Preformulation Studies of Livofloxacin as Nanoemulsion for Ocular Drug Delivery

Abstract

Objective: Levofloxacin is the L-isomer of the racemate ofloxacin, a quinolone antimicrobial agent. The objective of this article is to exhibit the quantitative methods used to determine consistency in developmental research. Author represented methods of preformulation for Levofloxacin as ocular nanoemulsion capable of delivering the drug in a sustained manner, thus avoiding frequent instillation of the drops which may induce toxic side effects and cellular damage at the ocular surface. Preformulation studies are essential to make sure the development of established as well as therapeutically safe and effective dosage form. Material and Methods: The preformulation studies, performed in this research include identification of drug, solubility analysis, and partition coefficient and drug compatibility. In current work entire preformulation study was carried out, which contain identification of drug, quantitative estimation of drug, solubility determination, melting point determination, partition coefficient determination, Screening etc. Results: The melting point of Levofloxacin was found to be 223–228°C. The log P value was found to be-0.34 ± 0.05, from which it can be interpreted that drug is highly Lipophilic in nature. The scanned λmax was found to be 298 nm. No significant changes were found when FTIR spectra of physical mixture compared with FTIR spectra of pure drug and excipients. This indicates the absence of any possible interaction between the drug and excipients which confirms the identity and purity of drug. Conclusion: These results propose that Levofloxacin serves as appropriate candidate for the ocular drug delivery system.